

ANNOUNCEMENT OF THE VOTING RESULTS **OF THE A.G.M ON THE 26TH OF JUNE 2023**

The Company "AUTOMATIC ANALYZERS - DIAGNOSTIC REAGENTS AND PRIVATE DIAGNOSTIC LABORATORIES MEDICON HELLAS A.E." and the distinctive title "MEDICON HELLAS S.A." announces, in accordance to the article 133 § 2 of Law 4548/2018, the results of the voting regarding the items on the agenda of the Annual General Meeting of shareholders on the 26th of June 2023, held at the Company's headquarters (Melitona 5 - 7, Gerakas Attikis, 1st floor), and at which, the shareholders were representing 3.333.910 common registered shares were present, in person or through their representatives, equal to the percentage of 75,4343% of the total 4,419,616 shares into which the company capital is divided, and an equal number of voting rights, which have per agenda item as follows:

1st subject of the daily agenda:

1] Submission and approval of the Annual Financial Statements (Corporate and Consolidated) of MEDICON HELLAS A.E. fiscal year 2022 (01.01.2022–31.12.2022), after the submission, hearing and approval of the Annual Report of the Board of Directors and the auditor's Audit Report.

Unanimously the annual management report (annual financial report), the Annual (corporate and consolidated) financial statements of the fiscal year 2022 (1.1.2022 – 31.12.2022), of MEDICON HELLAS A.E., as well as the report of the independent certified public accountant on them.

Number of shares for which valid votes were cast: 3.333.910

Percentage on share capital : 75,4343%

Valid : 3.333.910

Voting and percentages of the valid:

For: 3.333.910 (75,4343%) Against: 0 (0.00%) White/Abstain: 0 (0.00%)

2nd subject of the daily agenda:

2] Approval of profit allocation for the period 01.01.2022–31.12.2022.

It is noted that with the decision of 20-12-2022 the distribution of an interim dividend was approved, for the corporate year 2022 of a total amount of 500,000 Euro (gross amount), i.e. 0.1131320006 Euro per share of the Company (gross amount).

The ex-dividend date was set for Wednesday, March 1st 2023. Beneficiaries of the temporary dividend for the year 2022 were the registered in the archives of the Securities Exchange System (S.A.T.) on Thursday, March 2, 2023 (Record Date). The payment (payment) of the interim dividend for the year 2022 began on Monday, March 6, 2023, and was held by the company HELLENIC CENTRAL DEPOSITORY OF SECURITIES (ATHEXCSD), through Participants of the securities accounts in the SAT.

The distribution of a total amount of dividend for the year 2022 was approved at Euro 176,784.64 or Euro 0.04 per share. Entitlement cut-off date set Monday July 10, 2023 - Beneficiary file date set on Tuesday 11 July 2023 and payment start date Monday 17 July 2023.

Therefore, the total amount of dividend for the year 2022 amounts to Euros 676,784.64 or Euro 0.1531320006 per share.

Number of shares for which valid votes were cast: 3.333.910

Percentage on share capital : 75,4343%

Valid : 3.333.910

Voting and percentages of the valid:

For: 3.333.910 (75,4343%) Against: 0 (0.00%) White/Abstain: 0 (0.00%)

3rd subject of the daily agenda:

3] Approval of the overall management of the Board of Directors for the corporate year 01.01.2022-31.12.2022 according to article 108 of Law 4548/2018 and exemption of the Company's Auditors from any responsibility of reimbursement for the corporate year 2022, as well as for the Annual Financial Statements of the year 2022 according to article 117 par. 1 c. of Law 4548/2018.

The overall management of the Company's affairs was approved by the Board of Directors fiscal year 2022.

The release of the Certified Auditors-Accountants from any liability was approved compensation for the deeds of the corporate year 2022.

Number of shares for which valid votes were cast: 3.333.910

Percentage on share capital : 75,4343%

Valid : 3.333.910

Voting and percentages of the valid:

For: 3.333.910 (75,4343%) Against: 0 (0.00%) White/Abstain: 0 (0.00%)

4th subject of the daily agenda:

4] Submission for discussion and voting by the Annual General Meeting of the Remuneration Report for the corporate year 01.01.2022-31.12.2022 in accordance with article 112 of Law 4548/2018, as applicable.

Submitted for discussion and approved (advisory) without no comments the Remuneration Report for the corporate year 1.1.2022 – 31.12.2022 in accordance with article 112 of Law 4548/2018, as applicable.

Number of shares for which valid votes were cast: 3.333.910

Percentage on share capital : 75,4343%

Valid : 3.333.910

Voting and percentages of the valid:

For: 3.333.910 (75,4343%) Against: 0 (0.00%) White/Abstain: 0 (0.00%)

5th subject of the daily agenda:

5] Approval of the payments, salaries and compensations of the members of the Company's Board of Directors, the Audit Committee and the Executives for the corporate year 01.01.2022-31.12.2022 according to article 109 of Law 4548/2018.

All the fees and compensations of the members of the Administrative Board were approved Council for the year 2022, based on the pre-approval of the previous Rules General Meeting.

Number of shares for which valid votes were cast: 3.333.910

Percentage on share capital : 75,4343%

Valid : 3.333.910

Voting and percentages of the valid:

For: 3.333.910 (75,4343%) Against: 0 (0.00%) White/Abstain: 0 (0.00%)

6th subject of the daily agenda:

6] Approval of contracts, approval and pre-approval and determination of salaries, fees and compensations paid during the 2022-2023 financial years to the members of the Board of Directors, the Audit Committee and the Executives as well as granting permission for advance payment of the remuneration to these members, for the period of time until the next Ordinary General Meeting in accordance to articles 109 and 117 of Law 4548/2018.

The General Assembly, after a dialogical discussion, accepts the proposal Board of Directors, and decides with 3,333,910 votes in favor, 0 against and votes 0 White/Abstain, i.e. with a percentage of 75.4343%

It provides the Board with the mandate and authority to monitor and execute this decision, in accordance with the Law.

7th subject of the daily agenda:

7] Provision of approval - permission to enter into employment contracts or mandates of the company with members of its Board of Directors and setting an upper limit of their salaries.

Permission is granted to enter into contracts of employment or mandate of the company with members of the Board of Directors. Salaries will not exceed the limits set in the 6th topic of the Agenda.

Number of shares for which valid votes were cast: 3.333.910

Percentage on share capital : 75,4343%

Valid : 3.333.910

Voting and percentages of the valid:

For: 3.333.910 (75,4343%) Against: 0 (0.00%) White/Abstain: 0 (0.00%)

8th subject of the daily agenda:

8] Submission and presentation of the audit committee's annual report for the 2022 financial year (01.01.2022-31.12.2022).

The shareholders were informed about the annual report Audit Committee, in accordance with article 44 par. 1 of Law 4449/2017, in which the description of the sustainable development policy followed by Company. The Annual Report of the Audit Committee is intended to inform the shareholders about the actions of the Committee during the corporate year 1/1/2022 - 31/12/2022 and therefore no vote follows.

The full text of the Proceedings Report has been posted and is available at investment public on the Company's website <http://www.mediconsa.com>.

9th subject of the daily agenda:

9] Election of an Audit Company for the Regular Audit of the Financial Statements (Corporate and consolidated) of MEDICON HELLAS A.E., in accordance with the International Financial Reporting Standards, of the management period 01.01.2023 - 31.12.2023 and determination of its salary figure.

The election of the auditing firm of Certified Auditors-Accountants was approved "AUDITASK CERTIFIED AUDITORS ACCOUNTANTS BUSINESS ADVISORS JOINT STOCK COMPANY" and the d.t. "JPA AUDIT GREECE" for the use 1.1.2023 – 31.12.2023 and their remuneration was set. Furthermore, the regular Auditor was appointed, as well as the substitute Statutory Auditor. The responsibility of the control will be at

independent statutory auditor (one regular Auditor and one substitute) that the aforementioned auditing company will designate. Approved the remuneration of the above Auditing Company for the year 2023.

Number of shares for which valid votes were cast: 3.333.910

Percentage on share capital : 75,4343%

Valid : 3.333.910

Voting and percentages of the valid:

For: 3.333.910 (75,4343%) Against: 0 (0.00%) White/Abstain: 0 (0.00%)

10th subject of the daily agenda:

10] Provision of permission in accordance with article 98 par. 1 of Law 4548/2018, as applicable, to the members of the Board of Directors and the managers of the Company to participate in Boards of Directors or in the management of the subsidiaries, relatives and associated companies of the Group, which pursue similar and/or related purposes.

The permission of the General Assembly was unanimously granted to all the members of the Company's board of directors, as they participate in the administration (under any capacity, that of director, manager, administrator or even member boards of directors) and other affiliated and non-affiliated companies, the which pursue similar and/or similar purposes.

Number of shares for which valid votes were cast: 3.333.910

Percentage on share capital : 75,4343%

Valid : 3.333.910

Voting and percentages of the valid:

For: 3.333.910 (75,4343%) Against: 0 (0.00%) White/Abstain: 0 (0.00%)

11th subject of the daily agenda:

11] Submission to the General Assembly, of the Report of the Independent Non-Executive Members of the Board of Directors in accordance with article 9 par. 5 of Law 4706/2020 as applicable.

The shareholders were informed regarding the annual report of the Independent non-Executive Members of the Board of Directors in accordance with article 9 par. 5 thereof Law 4706/2020 as applicable.

The full text of its Independent Non-Executive Members' Report Administrative Council has been posted and is available to the investing public on the website of the company <http://www.mediconsal.com> .

12th subject of the daily agenda:

12] Announcement of the election of a new member of the Board of Directors to replace a resigned one. Decision on the appointment or election of a new member until the end of the term of office of the above resigned member.

The President of the General Meeting informs that Ms. Maria – Eleni Dimotsantou of Spyridonos, Vice President of the Board of Directors-Non-executive member submitted her resignation, which was accepted. The Board of Directors based on the relevant proposal of the Nomination Committee Nominations, formulated with a view to fulfilling the conditions and the criteria provided by the current regulatory framework and the Company's Operating Regulations and the Regulations and Policies that govern the applicable corporate governance framework, chose Ms. Sotiria Mitropoulou of Chrysanthos as its new Vice-President and non-executive member Board of Directors, in place of the resigned Ms. Maria – Eleni Dimotsantou of Spyridonos, for the remainder of her term until June 30, 2026 and is automatically extended, in accordance with the Law and the Statute, until the date of the Ordinary General Assembly to be convened after that date.

After the above announcement, the President makes a recommendation to the General Meeting the approval – validation of the election of Ms. Sotiria Mitropoulou Chrysanthou as the new Vice-President and non-executive member of the Board of Directors, in replacement of the resigned Ms. Maria – Eleni Dimotsantou Spyridon.

It is noted that the evaluation of the composition of the Board of Directors by the Remuneration and Nominations Committee, and the formulation of the relevant recommendation of the election of Ms. Sotiria Mitropoulou of Chrysanthos, as the new Vice-Chairman and non-executive member of the Board of Directors, replacing the resigned Mrs. Maria – Eleni Dimotsantou of Spyridon, according to below specifically mentioned, aims to essentially ensure that the Board of Directors and its Committee have the appropriate balance knowledge, skills, experience and diversity for effective practice of their duties, both from a collective point of view, and in terms of what was proposed and already elected as above new member of the Board of Directors, which has assessed as fully suitable and sufficient to contribute effectively in the work of the Board of Directors and to demonstrate commitment to his role based on the general strategy and medium-long-term business pursuits of the Company and with the aim of promoting the corporate interest.

For the evaluation of the candidacy of Ms. Sotiria Mitropoulou Chrysanthou as the new Vice-President and non-executive member of the Board, the Committee of Remuneration and Nominations took into account in particular:

- The Company's Operating Regulations,
<https://www.mediconsa.com/kanonismoikai-katastatiko> .

- The approved Suitability Policy of the members of the Board of Directors, <https://www.mediconsa.com/kanonismoi-kai-katastatiko> .
- The Greek Code of Corporate Governance, adopted and applied by the Company , <https://www.mediconsa.com/kanonismoi-kai-katastatiko> .
- The Operating Regulations of the Board of Directors [//https://www.mediconsa.com/kanonismoi-kai-katastatiko](https://www.mediconsa.com/kanonismoi-kai-katastatiko).
- The policy to prevent & combat violence and harassment in work, <https://www.mediconsa.com/kanonismoi-kai-katastatiko>.
- The policy of prevention, detection, management of situations, conflicts interests, <https://www.mediconsa.com/kanonismoi-kai-katastatiko> .
- The skills, experience, adequacy of knowledge, guarantees of ethics and reputation, the availability of sufficient time and the other qualifications of Ms. Sotiria Mitropoulos Chrysanthou, as these data are derived based on the detailed CV his note, which is listed on the Company's website https://www.mediconsa.com/sites/default/files/202301/MITROPOULOU_SOTIRIA_1.pdf , and the application of the applicable procedure attracting and selecting candidate members of the Board of Directors.
- The provisions of articles 1 to 24 of Law 4706/2020 on corporate governance, applied to joint-stock companies with shares or other transferable securities listed on a regulated market in Greece in addition to the provisions of Law 4548/2018. Based on the above, the Remuneration Committee and Nominations of the Company found that in the person of Ms. Sotiria Mitropoulou of Chrysanthos as its new Vice-President and non-executive member Board of Directors the suitability criteria for the members of the Board of Directors are met, which have been determined based on Article 3 of Law 4706/2020 Policy Eligibility approved by the Ordinary General Assembly of its shareholders of the Company of 30.06.2021, the Operating Regulations of the Company, summary of which is posted on the corporate website, its Operating Regulations Board of Directors and the other applicable regulatory framework.

In particular, it was established that Ms. Sotiria Mitropoulou of Chrysantho as the new Vice-president and non-executive member of the Board of Directors, meets all the individual criteria eligibility based on the Company's Eligibility Policy and specifically the adequacy of knowledge and skills, including academics and professional qualifications, to perform the duties of the role, the adequacy of his professional experience and the prerequisites from the Company's abilities, the absence of any obstacles or incompatibilities to his person, the moral and reputation guarantees, the non-existence of conflict interests, independence of judgment and the availability of sufficient time.

The election of Ms. Sotiria Mitropoulou of Chrysanthos is absolutely justified, as it has significant professional development over time, including the exercise of business activity, knowledge of structure of the Group, the sectors in which it operates, the business model of and the strategy it follows in general, knowledge and understanding

of the issues corporate governance and the relevant framework of the Company and deeply understanding the functioning of Boards of Directors. Ms. Sotiria Mitropoulou of Chrysanthos as a candidate member of the Board of Directors Council has submitted to the Company a declaration that it does not meet the impediment to the issuance, within the last year before his election, of a ultimatum court decision that recognizes his culpability for damages company transactions of Law 4548/2018 with related parties.

The detailed biography of Ms. Sotiria Mitropoulou of Chrysanthos has been posted on the company's website:

https://www.mediconsa.com/sites/default/files/202301/MITROPOULOU_SOTIRIA_1.pdf.

The Annual General Meeting accepted the proposal of its President and approved – ratified the election of Ms. Sotiria Mitropoulos of Chrysanthos as Vice President and non-executive member of the Board of Directors, replacing her of resigned Mrs. Maria – Eleni Dimotsantou of Spyridon, for remainder of the term of office of the said resigned, which expires on 30th.6.2026 and is automatically extended, in accordance with the Law and the Statute, until the date of the Ordinary General Assembly which will be convened after this date.

Number of shares for which valid votes were cast: 3.333.910

Percentage on share capital : 75,4343%

Valid : 3.333.910

Voting and percentages of the valid:

For: 3.333.910 (75,4343%) Against: 0 (0.00%) White/Abstain: 0 (0.00%)

13th subject of the daily agenda:

13] Various issues and announcements.

The company's future investments were discussed.

Gerakas Attica June 26, 2023

MEDICON HELLAS A.E.